Artificial intelligence (AI) is opening up new perspectives in the fight against cancer, one of humanity’s most challenging diseases. With the increasing use of advanced algorithms and machine learning, AI is revolutionizing oncology, enabling more accurate early detection, personalized treatment, and better patient management. Some of these studies come directly from Italy.
One of the areas where AI is proving particularly effective is early cancer detection. Machine learning algorithms can analyze large amounts of data, such as radiological images and genomic data, to identify early signs of cancer that could escape the human eye. This allows for a more timely and accurate diagnosis, allowing doctors to begin treatment before the disease spreads.
In addition, AI is helping to personalize cancer treatments. By analyzing clinical and genetic data, machine learning algorithms can identify a patient’s cancer subtypes and predict which therapy will be most effective for that particular patient. This avoids unnecessary or ineffective treatment and improves treatment outcome.
AI is also improving patient management oncological. AI-based monitoring systems can constantly collect and analyze patient clinical data, such as symptoms, treatment side effects, and test results, enabling more accurate and personalized treatment management. This can improve the quality of care and reduce unnecessary hospital admissions.
The University of Bologna is joining a European mission: the SYNTHEMA project. Their aim is to develop cutting-edge technologies that can overcome the current lack of data on rare diseases such as sickle cell anemia and acute myeloid leukemia.
Through the AI of "federated learning" the SYNTHEMA project allows you to start from the initial learning of a first partial learning from the various sites where data reside real data, - you can read on the website of the University of Bologna - and then complete the learning in a centralized server through the exchange with remote nodes of only locally learned parameters'.
The generated data has the same statistical properties as real data and has the advantage of not being subject to European privacy restrictions.
The National Cancer Institute of Milan is the leader of the international research project I3LUNG. The study, funded with 10 million euros by the EU, aims to identify, using the potential of artificial intelligence, different possible biomarkers to make patient-friendly, and therefore more effective, immunotherapy against this neoplasm.
According to the researcher Arsela Prelaj it would be possible to arrive at a better molecular profiling of the patient not with one, but with more biomarkers, to be identified by analyzing the clinical data. Some data are already available and some still to be collected. Even with the use of AI, much more efficient than conventional methods in identifying correlations and salient information, perhaps so far overlooked by researchers.
Viola Meacci, student of Biomedical Engineering at the University of Pisa, has always been interested in the world of journalism. In her job, she explored the world of blockchain, cryptocurrencies, NFT and metaverse which she now very is passionate about it .